Seqirus Announces U.S. FDA Approval for Multi-Dose Vial Presentation of First-Ever Adjuvanted, Cell-Based Pandemic Influenza Vaccine
/PRNewswire/ -- The FDA has granted approval of multi-dose vial presentation for AUDENZ™ to help protect individuals six months of age and older against...
Source: prnewswire.com